Mineralys Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on April 1st to discuss the results of its lorundsrostat trial in hypertension. The event will feature Dr. Luke Laffin from the Cleveland Clinic and will address challenges faced by uncontrolled and resistant hypertension.
Mineralys is developing lorundsrostat, an oral aldosterone synthase inhibitor, as a treatment for various cardiorenal conditions. The company’s focus on proprietary product candidate lorundsrostat underlines its commitment to innovative solutions in cardiorenal conditions.
However, Mineralys Therapeutics is still in a clinical-stage phase, which may raise concerns about its current viability and financial stability. Additionally, the press release does not provide any updates on the trial’s success or potential regulatory approval.
Investor relations can find more information on Mineralys Therapeutics’ website.
Source: https://www.nasdaq.com/articles/mineralys-therapeutics-host-conference-call-advance-htn-and-launch-htn-clinical-trial